BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $13.63 billion. The enterprise value is $13.13 billion.
| Market Cap | 13.63B |
| Enterprise Value | 13.13B |
Important Dates
The next estimated earnings date is Wednesday, April 23, 2025, after market close.
| Earnings Date | Apr 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BMRN has 190.78 million shares outstanding. The number of shares has increased by 2.67% in one year.
| Current Share Class | 190.78M |
| Shares Outstanding | 190.78M |
| Shares Change (YoY) | +2.67% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 0.86% |
| Owned by Institutions (%) | 91.92% |
| Float | 178.45M |
Valuation Ratios
The trailing PE ratio is 32.37 and the forward PE ratio is 16.60. BMRN's PEG ratio is 0.91.
| PE Ratio | 32.37 |
| Forward PE | 16.60 |
| PS Ratio | 4.76 |
| Forward PS | 4.26 |
| PB Ratio | 2.41 |
| P/TBV Ratio | 2.65 |
| P/FCF Ratio | 27.96 |
| P/OCF Ratio | 23.79 |
| PEG Ratio | 0.91 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.69, with an EV/FCF ratio of 26.93.
| EV / Earnings | 30.75 |
| EV / Sales | 4.60 |
| EV / EBITDA | 19.69 |
| EV / EBIT | 23.03 |
| EV / FCF | 26.93 |
Financial Position
The company has a current ratio of 5.33, with a Debt / Equity ratio of 0.11.
| Current Ratio | 5.33 |
| Quick Ratio | 2.96 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.93 |
| Debt / FCF | 1.30 |
| Interest Coverage | 45.01 |
Financial Efficiency
Return on equity (ROE) is 8.05% and return on invested capital (ROIC) is 5.76%.
| Return on Equity (ROE) | 8.05% |
| Return on Assets (ROA) | 5.15% |
| Return on Invested Capital (ROIC) | 5.76% |
| Return on Capital Employed (ROCE) | 8.93% |
| Revenue Per Employee | $938,788 |
| Profits Per Employee | $140,414 |
| Employee Count | 3,040 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 0.50 |
Taxes
In the past 12 months, BMRN has paid $114.90 million in taxes.
| Income Tax | 114.90M |
| Effective Tax Rate | 21.21% |
Stock Price Statistics
The stock price has decreased by -19.38% in the last 52 weeks. The beta is 0.33, so BMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -19.38% |
| 50-Day Moving Average | 67.39 |
| 200-Day Moving Average | 73.49 |
| Relative Strength Index (RSI) | 55.89 |
| Average Volume (20 Days) | 1,459,215 |
Short Selling Information
The latest short interest is 4.77 million, so 2.50% of the outstanding shares have been sold short.
| Short Interest | 4.77M |
| Short Previous Month | 4.24M |
| Short % of Shares Out | 2.50% |
| Short % of Float | 2.67% |
| Short Ratio (days to cover) | 2.97 |
Income Statement
In the last 12 months, BMRN had revenue of $2.85 billion and earned $426.86 million in profits. Earnings per share was $2.21.
| Revenue | 2.85B |
| Gross Profit | 2.27B |
| Operating Income | 570.04M |
| Pretax Income | 298.68M |
| Net Income | 426.86M |
| EBITDA | 666.47M |
| EBIT | 570.04M |
| Earnings Per Share (EPS) | $2.21 |
Balance Sheet
The company has $1.14 billion in cash and $633.97 million in debt, giving a net cash position of $503.74 million or $2.64 per share.
| Cash & Cash Equivalents | 1.14B |
| Total Debt | 633.97M |
| Net Cash | 503.74M |
| Net Cash Per Share | $2.64 |
| Equity (Book Value) | 5.66B |
| Book Value Per Share | 29.66 |
| Working Capital | 2.63B |
Cash Flow
In the last 12 months, operating cash flow was $572.84 million and capital expenditures -$85.42 million, giving a free cash flow of $487.42 million.
| Operating Cash Flow | 572.84M |
| Capital Expenditures | -85.42M |
| Free Cash Flow | 487.42M |
| FCF Per Share | $2.55 |
Margins
Gross margin is 79.67%, with operating and profit margins of 19.97% and 14.96%.
| Gross Margin | 79.67% |
| Operating Margin | 19.97% |
| Pretax Margin | 18.98% |
| Profit Margin | 14.96% |
| EBITDA Margin | 23.35% |
| EBIT Margin | 19.97% |
| FCF Margin | 17.08% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.67% |
| Shareholder Yield | -2.67% |
| Earnings Yield | 3.13% |
| FCF Yield | 3.58% |
Analyst Forecast
The average price target for BMRN is $94.00, which is 31.58% higher than the current price. The consensus rating is "Buy".
| Price Target | $94.00 |
| Price Target Difference | 31.58% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (5Y) | 7.95% |
| EPS Growth Forecast (5Y) | 27.97% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 7.99 and a Piotroski F-Score of 7.
| Altman Z-Score | 7.99 |
| Piotroski F-Score | 7 |